Publish with Nova Science Publishers
We publish over 800 titles annually by leading researchers from around the world. Submit a Book Proposal Now!
Kacper Rogóż, Dorota Bartusik-Aebisher and David Aebisher
Medical College of The University of Rzeszów, Poland
Part of the book: The Biochemical Guide to Proteins
HER2 is a receptor belonging to the 185 kDa family of epidermal growth factor (EGB) receptors. Under physiological conditions, it is responsible for the regulation of the cell cycle, proper growth and proliferation of the cell. The HER2 protein plays a significant role in the vital processes of the cells in the human body. Overexpression or amplification of the gene encoding this membrane receptor can lead to oncotic, enhanced cell proliferation and growth. Research that uses electromagnetic radiation, such as computed tomography and magnetic resonance imaging, is particularly important. Current research on trastuzumab and its combination with other cytotoxic drugs shows promising results. It is important to understand the mechanism of action of this monoclonal antibody on overexpression/amplification on HER2 receptors. Herceptin may in the future prove to be a breakthrough component of the drug that inhibits cancer cells.
Keywords: HER2, epidermal growth factor (EGF), tumor cell, vinorelbine,
capecitabine, computed tomography (CT), positron emission tomography (PET)
Kreutzfeldt J, Rozeboom B, Dey N, De P. The trastuzumab era: current and upcoming
targeted HER2+ breast cancer therapies. Am. J. Cancer Res. 2020;10(4):1045-1067.
Kunte S, Abraham J, Montero A J. Novel HER2-targeted therapies for HER2-positive
metastatic breast cancer. Cancer. 2020;126(19):4278-4288.
Ocaña A, Amir E, Pandiella A. HER2 heterogeneity and resistance to anti-HER2 antibody drug conjugates.
Breast Cancer Res. 2020;22(1):15.
Oh D Y, Bang Y J. HER2-targeted therapies – a role beyond breast cancer. Nat. Rev. Clin.
Pernas S, Tolaney S M. HER2-positive breast cancer: new therapeutic frontiers and
overcoming resistance. Ther. Adv. Med. Oncol. 2019;11:1758835919833519.